Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Natalie De Jonge
Observed names:
N De Jonge,
N. De Jonge,
Natalie D. Jonge,
Natalie de Jonge
Institution:
Argenx (Belgium)
Observed institutions:
Vrije Universiteit Brussel,
Institut Jules Bordet,
Vlaams Instituut voor Biotechnologie,
Antwerp University Hospital,
VIB-VUB Center for Structural Biology,
Argenx (Belgium),
Vanderbilt University Medical Center
show all 7
OpenAlex ID:
A5080278557
Rejuvenation of CcdB-Poisoned Gyrase by an Intrinsically Disordered Protein Domain
2009
·
Natalie De Jonge
, Abel Garcia-Pino
, et al.
·
Molecular Cell
·
168
PDF
Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform
2015
·
Alex Klarenbeek
, Khalil El Mazouari
, et al.
·
mAbs
·
104
PDF
Substrate Recognition and Activity Regulation of the Escherichia coli mRNA Endonuclease MazF
2016
·
Valentina Zorzini
, Andrej Mernik
, et al.
·
Journal of Biological Chemistry
·
61
PDF
Four individually druggable MET hotspots mediate HGF-driven tumor progression
2014
·
Cristina Basilico
, Anna Hultberg
, et al.
·
Journal of Clinical Investigation
·
55
Energetic Basis of Uncoupling Folding from Binding for an Intrinsically Disordered Protein
2013
·
Igor Drobnak
, Natalie De Jonge
, et al.
·
Journal of the American Chemical Society
·
55
Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
2015
·
Anna Hultberg
, Virginia Morello
, et al.
·
Cancer Research
·
43
PDF
Structural Mimicry of Receptor Interaction by Antagonistic Interleukin-6 (IL-6) Antibodies
2016
·
Christophe Blanchetot
, Natalie De Jonge
, et al.
·
Journal of Biological Chemistry
·
33
PDF
Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy
2016
·
Marie Godar
, Virginia Morello
, et al.
·
Scientific Reports
·
30
PDF
Driving Forces of Gyrase Recognition by the Addiction Toxin CcdB
2009
·
Mario Simic
, Natalie De Jonge
, et al.
·
Journal of Biological Chemistry
·
28
PDF
VEGFR-1/Flt-1 inhibition increases angiogenesis and improves muscle function in a mouse model of Duchenne muscular dystrophy
2021
·
Jennifer Bosco
, Zhiwei Zhou
, et al.
·
Molecular Therapy — Methods & Clinical Development
·
24
Alternative interactions define gyrase specificity in the CcdB family
2012
·
Natalie De Jonge
, Mario Simic
, et al.
·
Molecular Microbiology
·
22
PDF
Structural and Thermodynamic Characterization of Vibrio fischeri CcdB
2009
·
Natalie De Jonge
, Walter Hohlweg
, et al.
·
Journal of Biological Chemistry
·
21
PDF
A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors.
2015
·
Philippe G. Aftimos
, Philippe Barthelemy
, et al.
·
Journal of Clinical Oncology
·
16
Purification and crystallization ofVibrio fischeriCcdB and its complexes with fragments of gyrase and CcdA
2007
·
Natalie De Jonge
, Lieven Buts
, et al.
·
Acta Crystallographica Section F Structural Biology and Crystallization Communications
·
11
PDF
The NHance® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients
2021
·
Philippe Aftimos
, Christian Rolfo
, et al.
·
Biomedicines
·
8
PDF
Crystallization of the C-terminal domain of the addiction antidote CcdA in complex with its toxin CcdB
2005
·
Lieven Buts
, Natalie De Jonge
, et al.
·
Acta Crystallographica Section F Structural Biology and Crystallization Communications
·
6
The clinical potential of ARGX-111, an afucosylated anti-MET antibody, in hematological malignancies and suppression of metastasis
2015
·
V. Hanssens
, N. De Jonge
, et al.
·
Annals of Oncology
·
3
Sequence-specific 1H, 15N and 13C resonance assignments of the 23.7-kDa homodimeric toxin CcdB from Vibrio fischeri
2009
·
Michal Respondek
, Lieven Buts
, et al.
·
Biomolecular NMR Assignments
·
3
ARGX-111 shows activity in MET-amplified patients in a phase-I study and in preclinical models of myeloid-derived suppressor cell (MDSC) depletion in the tumor microenvironment.
2016
·
Christian Diego Rolfo
, Philippe Georges Aftimos
, et al.
·
Journal of Clinical Oncology
·
2
Supplementary Methods and References from Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
2023
·
Anna Hultberg
, Virginia Morello
, et al.
Supplementary Tables S1-S7 from Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
2023
·
Anna Hultberg
, Virginia Morello
, et al.
PDF
Supplementary Figures S1-S7 from Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
2023
·
Anna Hultberg
, Virginia Morello
, et al.
Data from Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
2023
·
Anna Hultberg
, Virginia Morello
, et al.
Distinct HER2 distribution and homo-dimerization patterns on subpopulations of breast cancer cells − correlative light- and electron microscopy in liquid for cancer stem cell characterization
2016
·
D. Peckys
, N. De Jonge
·
European Journal of Cancer
Abstract P2-05-17: ARGX-111 depletes MET-expressing circulating tumor cells via enhanced ADCC, resulting in inhibition of metastasis
2016
·
V Morello
, A Hultberg
, et al.
·
Cancer Research
Show more works
View as search
Works count:
32
Citation count:
693
H-index:
13
I10-index:
14
Year
Topic
Type